Canaccord Genuity has initiated coverage on Heartflow Inc (HTFL) with a Buy rating, marking its first assessment of the company. The firm’s decision reflects an analysis of Heartflow's business, industry dynamics, and growth prospects.
Heartflow, headquartered in Mountain View, California, specializes in diagnosing coronary artery diseases. The company employs 699 full-time workers and went public on August 8, 2025. Its innovative HeartFlow Platform leverages AI and advanced computational fluid dynamics to create personalized 3D models of patients' hearts from a single coronary computed tomography angiography (CCTA). This platform includes tools such as Roadmap Analysis, FFRCT Analysis, and Plaque Analysis, which assist physicians in delivering precision care to patients with coronary artery disease (CAD).
As of November 20, 2025, Heartflow has a market capitalization of $2.4 billion. The company is set to report its upcoming earnings on November 12, 2025, with an estimated EPS of -$0.22 and revenue of $42.8 million. In its most recent earnings report for Q3 2025, Heartflow posted an EPS of -$0.35, falling short of expectations.
The analyst consensus for Heartflow shows 3 Strong Buy, 6 Buy, and 2 Hold ratings, indicating a general positive outlook among analysts. Recent actions include similar initiation ratings from Stifel, JP Morgan, and Piper Sandler on September 2, 2025.
Analysts' ratings and price targets are based on research and financial models. They should be considered alongside other factors such as company fundamentals and market conditions when making investment decisions.